On November 5, 2024 Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, reported that safety and tolerability data from patients treated with Descartes-08 will be featured during a poster presentation at the upcoming 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego (Press release, Cartesian Therapeutics, NOV 5, 2024, View Source [SID1234647740]). A copy of the abstract is available on the ASH (Free ASH Whitepaper) website at www.hematology.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen (BCMA).
Details of the poster presentation are as follows:
Publication Number: 2080
Title: Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Diseases
Presenter: Miloš Miljković, M.D., M.Sc., Chief Medical Officer, Cartesian Therapeutics
Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
Session Date/Time: Saturday, December 7, 2024, 5:30-7:30 p.m. PT
Location: San Diego Convention Center, Halls G-H
In addition, the poster was selected for inclusion in the ASH (Free ASH Whitepaper) Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights. The Poster Walk, which aims to highlight cutting-edge emerging science featured at the meeting, will take place on Monday, December 9, 2024, at 7:30 a.m. PT in the Blood Journal Studio located in the Poster Hall.
About Descartes-08
Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product targeting B-cell maturation antigen (BCMA) in clinical development for generalized myasthenia gravis (MG) and systemic lupus erythematosus. In contrast to conventional DNA-based CAR T-cell therapies, mRNA CAR-T administration is designed so that it does not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by the U.S. Food and Drug Administration for the treatment of MG.